Hyperparathyroidism, Secondary

"Hyperparathyroidism, Secondary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.

Descriptor ID	D006962
MeSH Number(s)	C19.642.355.480
Concept/Terms	Hyperparathyroidism, Secondary Hyperparathyroidism, Secondary Secondary Hyperparathyroidism Hyperparathyroidisms, Secondary Secondary Hyperparathyroidisms

Below are MeSH descriptors whose meaning is more general than "Hyperparathyroidism, Secondary".

Diseases [C]
Endocrine System Diseases [C19]
Parathyroid Diseases [C19.642]
Hyperparathyroidism [C19.642.355]
Hyperparathyroidism, Secondary [C19.642.355.480]

Below are MeSH descriptors whose meaning is related to "Hyperparathyroidism, Secondary".

Below are MeSH descriptors whose meaning is more specific than "Hyperparathyroidism, Secondary".

Hyperparathyroidism, Secondary
Chronic Kidney Disease-Mineral and Bone Disorder

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hyperparathyroidism, Secondary" by people in this website by year, and whether "Hyperparathyroidism, Secondary" was a major or minor topic of these publications.

Bar chart showing 6 publications over 5 distinct years, with a maximum of 2 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	1	0	1
2001	1	0	1
2002	0	1	1
2006	1	0	1
2008	1	1	2

Below are the most recent publications written about "Hyperparathyroidism, Secondary" by people in Profiles.

Alsafran S, Sherman SK, Dahdaleh FS, Ruhle B, Mercier F, Kaplan EL, Angelos P, Grogan RH. Preoperative calcitriol reduces postoperative intravenous calcium requirements and length of stay in parathyroidectomy for renal-origin hyperparathyroidism. Surgery. 2019 01; 165(1):151-157.

View in: PubMed
Omije D, Norris K, Wang J, Pan D, Kermah D, Gupta A. Race is a major determinant of secondary hyperparathyroidism in uremic patients: comparative study of Blacks and Hispanics. Clin Nephrol. 2008 Oct; 70(4):312-8.

View in: PubMed
Wolf M, Betancourt J, Chang Y, Shah A, Teng M, Tamez H, Gutierrez O, Camargo CA, Melamed M, Norris K, Stampfer MJ, Powe NR, Thadhani R. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol. 2008 Jul; 19(7):1379-88.

View in: PubMed
Norris KC. Oral paricalcitol : a viewpoint by keith C. Norris. Treat Endocrinol. 2006; 5(5):326-7.

View in: PubMed
Friedman TC, Norris KC. The role of vitamin D in mild to moderate chronic kidney disease. Trends Endocrinol Metab. 2002 Jul; 13(5):189-94.

View in: PubMed
Maung HM, Elangovan L, Fraz?o JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis. 2001 Mar; 37(3):532-43.

View in: PubMed
Fraz?o JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis. 2000 Sep; 36(3):550-61.

View in: PubMed
Salusky IB, Goodman WG, Horst R, Segre GV, Kim L, Norris KC, Adams JS, Holloway M, Fine RN, Coburn JW. Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. Am J Kidney Dis. 1990 Aug; 16(2):126-32.

View in: PubMed
Coburn JW, Norris KC, Sherrard DJ, Bia M, Llach F, Alfrey AC, Slatopolsky E. Toxic effects of aluminum in end-stage renal disease: discussion of a case. Am J Kidney Dis. 1988 Sep; 12(3):171-84.

View in: PubMed
Kleeman CR, Norris K, Coburn JW. Is the clinical expression of primary hyperparathyroidism a function of the long-term vitamin D status of the patient? Miner Electrolyte Metab. 1987; 13(5):305-10.

View in: PubMed

People

Explore

Similar Concepts

Top Journals